🌟 Exciting Opportunity at our partner institute 🌟 If you thrive in a dynamic environment and want to contribute to cutting-edge research with tangible impact, explore the career opportunity at our partner institute. UMC Utrecht: https://lnkd.in/dmqVDQGC Couldn’t find what you’re looking for? Keep an eye out for updates on our Careers page 👉 https://lnkd.in/eAw7ufiW
About us
Oncode Accelerator aims to optimize and accelerate the development of new cancer therapies to address the unmet medical need.
- Industry
- Research Services
- Company size
- 2-10 employees
- Type
- Nonprofit
- Founded
- 2023
- Specialties
- Oncology, Research, Cancer therapies, and preclinical therapeutic development
Employees at Oncode Accelerator
Updates
-
“There are exciting opportunities for cell and gene therapy in the Netherlands in the coming decades. Funding from Oncode Accelerator offers us a unique opportunity to consolidate our national and international position and increase access to these innovative therapies.” Read the full double-interview with Jurgen Kuball, chair of the CGT Workstream management team and head of the Department of Hematology at UMC Utrecht, and Inge Jedema, co-chair and head of Translational Cellular Therapy at The Netherlands Cancer Institute. ➡ https://lnkd.in/dSyxyQ5U #preclinical #drugdevelopment #healthdata #patientengagement #ai #patientcohorts #organoids #cellgenetherapy #smallmolecules #biologics #therapeuticvaccines #regulatoryinnovation #nationaalgroeifonds #NGF #oncology #cancerresearch #cancertherapy
-
-
Researchers supported by funding from Oncode Accelerator have just published a new, extensive protocol to create isogenic disease models from adult stem cell-derived organoids. They state that their method simplifies in vitro disease model generation, since they used next-generation CRISPR tools that do not require double-stranded break (DSB) induction for their function. ➡ Their protocol will be published in the September issue of STAR Protocols, and is already available as open access article online: https://lnkd.in/ehQsmnKc #preclinical #drugdevelopment #healthdata #patientengagement #ai #patientcohorts #organoids #cellgenetherapy #smallmolecules #biologics #therapeuticvaccines #regulatoryinnovation #nationaalgroeifonds #NGF #oncology #cancerresearch #cancertherapy
-
The annual report of the Dutch National Growth Fund (Nationaal Groeifonds, NGF) has been published. The link below includes the full report in Dutch, describing the activities of the initiatives funded by the NGF for the year 2023. Oncode Accelerator's ambition is to develop valuable cancer drug candidates faster and cheaper, to bring them to patients earlier and to create economical and societal value. As Oncode Accelerator is one of the initiatives funded by the NGF, the report covers the key expected economical and societal effects from the program: 🏥 Solutions against cancer result in health benefits and a better quality of life for cancer patients. This also reduces health care costs and potentially allows for people to become and remain more productive. 🐭 Using innovative technologies such as patient-derived organoid models, less animal models are required. In addition, this new technology aims to predict toxicity earlier as they serve as a better representation of the patient, versus classical animal models 💊 Reduction of development costs of cancer medicines as a basis for more affordable medicines. This means an increase in productivity and/or leads to higher added value for society. 💡Companies will sell new cancer drugs all over the world, have patents and financial flows in the Netherlands and manufacture from the Netherlands. 🌟 Attract investments from companies that want to develop their medicines in the Netherlands. Interested in keeping up-to-date with the progress of Oncode Accelator? Subscribe to stay connected: https://lnkd.in/ePf8SBTP #nationaalgroeifonds #NGF #oncodeaccelerator #drugdevelopment #oncology #cancerresearch
Adviescommissie presenteert jaarverslag 2023 Het jaarverslag van het Nationaal Groeifonds beschrijft de activiteiten van de adviescommissie over het jaar 2023. De onderdelen die in het rapport aan bod komen? Het doel van het fonds, de taken en het portfolio-overzicht. De adviescommissie betreurt dat er geen volgende rondes meer komen, maar geeft ook aan trots te zijn op de portefeuille en het verschil dat de 51 projecten gaan maken voor de toekomst van Nederland. Voorzitter van de adviescommissie Rianne Letschert: "Ik spreek namens de hele adviescommissie wanneer ik zeg dat de bijdrage van het Nationaal Groeifonds aan onze toekomst voor ons als een paal boven water blijft staan en dat het er nu op aankomt om de impact van onze programma’s te maximaliseren." 🔗Ga naar het nieuwsbericht en het jaarverslag: https://lnkd.in/eN7qtwUz #NationaalGroeifonds Rijksdienst voor Ondernemend Nederland (RVO) Ministerie van Economische Zaken Ministerie van Financiën
-
-
🤖 Quicker detection of breast cancer by AI 🤖 Researchers from the UMC Utrecht, showed that AI pathologists can help to assess the sentinel node in breast cancer patients more efficiently. This assessment is necessary to detect potential metastasis of breast cancer. Using AI for this detection makes the process more efficient, time saving and cheaper. The pathologists at UMC Utrecht are now working with the AI assistant as standard in breast cancer, probably as the first in the world. You can read the whole publication in Nature Cancer via the link below 👇 https://lnkd.in/dg7TXn9W
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial - Nature Cancer
nature.com
-
📢 Save the date! 📢 The Oncode Accelerator Summit will be organised on November 28th at the Eye Filmmuseum in Amsterdam. Hear from expert speakers how innovation accelerates the development of new cancer therapies. Gain understanding on the value of demonstrator projects and how to join. Subscribe via the link below to receive updates on speakers and registration👇 https://lnkd.in/eS375kkA
-
-
🔬 CAR T-cell therapy further explored 🔬 For a long time, the perception has been that CAR T-cell therapy has little potential in the treatment of solid tumors. However, a recent publication showed that CAR T-cell therapy could have effect in solid tumors. The effect is still limited but there is already follow-up research that gives reason to think that future prospects are better. Workstream lead Cell and Gene therapy, John Haanen, is leader of the immunotherapy research theme and program director of the Center for Cell Therapy at our partner, the Antoni van Leeuwenhoek. He describes the developments in the world of CAR T-cells in the article below. 👇
Toepassing CAR T-celtherapie verkend voor solide tumoren | MedNet
https://www.mednet.nl
-
🌟 Interesting to read! 🌟 Read the first blog by the Oncode Accelerator team on the network of the Federation of European Biochemical Societies (FEBS). The blog will give you more insight about the Innovation Platforms and Workstreams within the program and our first call for Demonstrator Projects. Read the blog via the link below 👇 #FEBS #CancerResearch #Innovation
Do you work in the development of preclinical cancer therapies? The Oncode Accelerator program has an open call for Demonstrator Projects. They offer access to state-of-the-art equipment, expertise, facilities and technologies towards the development of cancer therapies up to early clinical validation. Their aim is to eventually turn assets into de-risked clinical candidates. Demonstrator Projects applicants may be eligible for up to 50% co-funding (maximum of €1.5 million per Demonstrator Project). The Oncode Accelerator program is a network of public and private partnerships from the Netherlands, including Leiden University, Leiden University Medical Center, the The Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht and the Oncode Accelerator Foundation. They receive funding from the Dutch National Growth Fund. Find out more on this FEBS Network post: https://lnkd.in/d8dXKipY
Oncode Accelerator: The call for Demonstrator Projects is open!
network.febs.org
-
🌟 Let's keep in touch! 🌟 Are you interested in staying up-to-date with developments of our program and how we progress towards our mission to outsmart cancer and impact lives? Join our mailing list to receive our Digital Magazine, updates about Demonstrator Projects, invitations to events and webinars and more interesting news and developments. 📩 Subscribe today via the link below👇 https://lnkd.in/g6Fk375S
Subscribe to stay connected | Oncode Accelerator
oncodeaccelerator.nl
-
📢 The first call is open! 📢 In April, Oncode Accelerator announced the opening of the first call for the Demonstrator Projects. What is in it for you? Oncode Accelerator provides you with access to state-of-the-art equipment, world-class research institutes and industry, top scientists, and a dedicated team to manage the process of your Demonstrator Project from the start to the finish. Besides, a Demonstrator Project can receive co-funding from Oncode Accelerator. Oncode Accelerator invites all parties interested in our unique approach to apply for a Demonstrator Project focused on the preclinical development of cancer therapies. Read more about the Demonstrator Projects via the link below 👇
What we offer | Oncode Accelerator
oncodeaccelerator.nl